DiCE gets its 'library' card ready as it speeds development of DNA database-derived molecules with more investor cash
Investors like to see big plans, and Kevin Judice has plenty. The DiCE Molecules CEO is plotting a clinical trial launch for the biotech’s lead small molecule for psoriasis and wants to double the staff in the next year and a half.
On Friday, those big plans landed him an $80 million Series C round.
“We’re very excited about it,” he said of the raise led by RA Capital Management.
The round comes around two years after a $50 million Series B. While the B round was used for optimizing technology and building a pipeline, Judice says the Series C will propel the biotech’s IL-17 antagonist to the clinic and fund the development of two other undisclosed programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
